Group 1 - The core viewpoint of the news highlights the recent performance and financial status of Rui Li Medical Beauty, indicating a mixed performance in the stock market and financial results [1][2]. - As of August 21, the Hang Seng Index fell by 0.24%, while Rui Li Medical Beauty's stock price increased by 11.67% to HKD 0.134 per share, with a trading volume of 2.114 million shares and a turnover of HKD 280,800 [1]. - Over the past month, Rui Li Medical Beauty has seen a cumulative increase of 5.26%, and a year-to-date increase of 12.15%, which is lower than the Hang Seng Index's increase of 25.45% [1]. Group 2 - Financial data shows that for the year ending December 31, 2024, Rui Li Medical Beauty achieved total revenue of CNY 199 million, a year-on-year increase of 5.26%, while the net profit attributable to shareholders was a loss of CNY 59.212 million, a decrease of 82.43% [1]. - The gross profit margin stands at 35.82%, and the debt-to-asset ratio is 61.78% [1]. - Currently, there are no institutional investment ratings for Rui Li Medical Beauty [1]. Group 3 - Rui Li Medical Beauty is a leading provider of medical beauty services in Zhejiang Province, China, offering a wide range of services including cosmetic surgery, minimally invasive beauty services, and skin beauty services [2]. - The company also provides medical beauty management consulting services to third-party medical beauty institutions and has begun to develop a sales network for medical beauty equipment products [2]. - As of December 31, 2021, Rui Li Medical Beauty operated four private profit-making medical beauty service institutions in China, with an average industry experience of over ten years among its more than 30 practicing physicians [2].

Core Viewpoint - Ruili Medical Beauty (02135) anticipates a decline in revenue and an increase in losses for the six months ending June 30, 2025, compared to the same period in 2024 [1] Financial Performance - Expected revenue for the six months ending June 30, 2025, is approximately RMB 85 million, down from RMB 117 million for the same period in 2024 [1] - Anticipated loss attributable to the parent company for the six months ending June 30, 2025, is approximately RMB 8 million, compared to a loss of RMB 2 million for the same period in 2024 [1] Reasons for Loss - The board attributes the loss primarily to intense market competition, resulting in a total revenue decline of approximately RMB 32 million compared to the same period in 2024 [1] - The medical beauty services and medical beauty management consulting services segment experienced an operational loss of approximately RMB 2 million during the reporting period [1] - Share-based payment expenses during the reporting period amounted to approximately RMB 1 million [1] - Increased investment in research and development for medical device products, particularly in the indirect non-wholly owned subsidiary Suzhou Ruichuan Biomedical Technology Co., Ltd., with management and R&D expenses of approximately RMB 1 million [1]

Core Viewpoint - Ruili Medical Beauty (02135) anticipates a decline in revenue and an increase in losses for the six months ending June 30, 2025, compared to the same period in 2024 [1] Financial Performance - Expected revenue for the six months ending June 30, 2025, is approximately RMB 85 million, down from RMB 117 million for the same period in 2024 [1] - Anticipated loss attributable to the parent company for the six months ending June 30, 2025, is approximately RMB 8 million, compared to a loss of RMB 2 million for the same period in 2024 [1] Reasons for Loss - The board attributes the loss primarily to intense market competition, resulting in a total revenue decline of approximately RMB 32 million compared to the same period in 2024 [1] - The medical beauty services and medical beauty management consulting services segment is expected to incur an operational loss of approximately RMB 2 million during the reporting period [1] - Share-based payment expenses are estimated at approximately RMB 1 million during the reporting period [1] - Increased investment in research and development for medical device products, particularly in the indirect non-wholly owned subsidiary Suzhou Ruichuan Biomedical Technology Co., Ltd., with management and R&D expenses amounting to approximately RMB 1 million [1]

Group 1 - The core viewpoint of the news highlights the recent performance of Rui Li Medical Beauty, which saw a stock price increase of 9.32% despite a cumulative decline of 6.35% over the past month, while the Hang Seng Index dropped by 1.6% [1][2] - Financial data indicates that Rui Li Medical Beauty achieved total revenue of 199 million yuan, a year-on-year increase of 5.26%, but reported a net loss of 59.21 million yuan, a significant decrease of 82.43% compared to the previous year [2] - The company's gross profit margin stands at 35.82%, with a debt-to-asset ratio of 61.78% [2] Group 2 - Currently, there are no institutional investment ratings for Rui Li Medical Beauty, and its price-to-earnings ratio is -1.03, ranking 101st in the healthcare equipment and services industry, which has an average TTM P/E ratio of -1.13 [3] - The company operates as a leading medical beauty service provider in Zhejiang, China, offering a wide range of services including cosmetic surgery, minimally invasive beauty services, and skin beauty services, along with consulting services for third-party medical beauty institutions [4] - Rui Li Medical Beauty has expanded its service network over 14 years, operating four private profit-making medical beauty service institutions in China, with over 30 practicing physicians averaging more than ten years of industry experience [4]

Company Overview - Rui Li Medical Beauty International Holdings Limited is a leading provider of medical beauty services in Zhejiang Province, China, focusing on meeting diverse customer needs in beauty and anti-aging [4] - The company offers a wide range of medical beauty services, including surgical beauty services, minimally invasive beauty services, and skin beauty services, as well as management consulting services for third-party medical beauty institutions [4] - Rui Li Medical has expanded into the sales network of medical beauty equipment, focusing on surgical implants and skincare products [4] Financial Performance - As of December 31, 2024, Rui Li Medical achieved total revenue of 199 million yuan, representing a year-on-year growth of 5.26% [2] - The company reported a net profit attributable to shareholders of -59.21 million yuan, a significant decrease of 82.43% year-on-year [2] - The gross profit margin stood at 35.82%, while the debt-to-asset ratio was 61.78% [2] Market Position and Valuation - Over the past month, Rui Li Medical has experienced a cumulative decline of 10.24%, while year-to-date, it has seen a cumulative increase of 6.54%, underperforming the Hang Seng Index's increase of 25.27% [2] - Currently, there are no institutional investment ratings for Rui Li Medical, and its price-to-earnings ratio is -0.99, ranking 101st in the industry [3] - The average price-to-earnings ratio for the healthcare equipment and services industry is -1.96, with a median of 1.36 [3]